Healthcare [ 3/11 ] | Biotechnology [ 47/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 23 | 1.02 Increased by +169.86% | 1.35 Decreased by -24.44% |
| May 4, 23 | -1.56 Decreased by -9.86% | -1.42 Decreased by -9.86% |
| Feb 21, 23 | -1.50 Increased by +6.83% | -1.57 Increased by +4.46% |
| Nov 7, 22 | -1.75 Increased by +23.25% | -1.45 Decreased by -20.69% |
| Aug 8, 22 | -1.46 Increased by +46.32% | -1.36 Decreased by -7.35% |
| May 4, 22 | -1.42 Increased by +38.79% | -1.32 Decreased by -7.58% |
| Feb 28, 22 | -1.61 Decreased by -273.12% | -1.54 Decreased by -4.55% |
| Nov 8, 21 | -2.28 Decreased by -27.37% | -1.70 Decreased by -34.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 94.97 M Increased by +481.85% | -122.04 M Increased by +21.76% | Decreased by -128.50% Increased by +86.55% |
| Mar 31, 23 | 44.85 M Increased by +211.84% | -177.78 M Decreased by -27.96% | Decreased by -396.42% Increased by +58.97% |
| Dec 31, 22 | 22.66 M Decreased by -62.41% | -165.99 M Decreased by -12.21% | Decreased by -732.43% Decreased by -198.50% |
| Sep 30, 22 | 22.06 M Increased by +290.37% | -191.27 M Increased by +2.20% | Decreased by -867.20% Increased by +74.95% |
| Jun 30, 22 | 16.32 M Increased by +2.52 K% | -155.98 M Increased by +28.84% | Decreased by -955.62% Increased by +97.28% |
| Mar 31, 22 | 14.38 M Increased by +N/A% | -138.94 M Increased by +24.35% | Decreased by -966.10% Decreased by N/A% |
| Dec 31, 21 | 60.29 M Decreased by -75.88% | -147.93 M Decreased by -289.02% | Decreased by -245.37% Decreased by -883.78% |
| Sep 30, 21 | 5.65 M Increased by +774.61% | -195.57 M Decreased by -44.12% | Decreased by -3.46 K% Increased by +83.52% |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.